Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc (NQ: CMND )

0.1560 UNCHANGED
Streaming Delayed Price Updated: 3:59 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Clearmind Medicine Inc

< Previous 1 2 3 Next >
Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland's Consumption Site & More
Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next 
Via Benzinga
Exposures Product Safety
Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind's $2.25M Public Offering
Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies 
Via Benzinga
Nasdaq Surges 100 Points; First Wave BioPharma Shares Spike Higher
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.93% to 34,898.47 while the NASDAQ rose 0.75% to 13,917.44.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi. 
Via Benzinga
Why Is IN8bio (INAB) Stock Up 9% Today?
IN8bio (INAB) stock is rising higher on Wednesday as the biopharmaceutical company's shares continue their wild swings this week. 
Via InvestorPlace
Crude Oil Rises Sharply; BIOLASE Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded up 0.61% to 34,784.94 while the NASDAQ rose 0.71% to 13,911.78. The S&P... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Clearmind Medicine Stock Is Getting Hammered Today
Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 53% to $0.18 Thursday morning after the company announced pricing of a $2.25 million public offering. The offering is expected to close... 
Via Benzinga
Dow Jumps Over 200 Points; US Producer Prices Rise In August
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.71% to 34,820.58 while the NASDAQ rose 0.27% to 13,849.49. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading. 
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed
Specialty clinical-stage biopharma company SciSparc Ltd. (NASDAQ: SPRC) has received a Nasdaq notice granting the company an additional 180-day compliance period until March 4 to regain compliance with... 
Via Benzinga
Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program
Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical... 
Via Benzinga
EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio
Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of... 
Via Benzinga
Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd. 
Via Benzinga
MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period
Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of... 
Via Benzinga
Why DXC Technology Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Gainers Monogram Orthopaedics Inc. (NASDAQ: MGRM) shares surged 163.7% to $30.98 in pre-market trading after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of... 
Via Benzinga
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Friday, May 12, 2023: CMCSA, KR, ON, TSVT, CMND
Comcast (CMCSA) - The parent company of NBCUniversal. One of Friday's most-discussed stories stemmed from a tweet by Elon Musk he had found a new exec to file the chief exec role at Twitter. 
Via Benzinga
EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment
Clearmind Medicine Inc. 
Via Benzinga
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction
Alcohol Use Disorder (AUD) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine (NASDAQ: CMND), the Israel-based company is going at it through its... 
Via Benzinga
Why Meta Platforms Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its... 
Via Benzinga
Why Is ZyVersa Therapeutics (ZVSA) Stock Down 46% Today?
ZyVersa Therapeutics (ZVSA) stock is sliding lower on Wednesday following a couple of announcements from the biopharmaceutical company. 
Via InvestorPlace
Why Chipotle Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Crown ElectroKinetics Corp. (NASDAQ: CRKN) shares jumped 105% to $0.1730 after the company issued a letter to shareholders. 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Is Clearmind Medicine (CMND) Stock Up 45% Today?
Clearmind Medicine (CMND) stock is taking off on Wednesday even without any recent news from the psychedelic medicine company. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time for another dive into the biggest pre-market stock movers that investors need to know about on Wednesday morning! 
Via InvestorPlace
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
SciSparc And Clearmind Collaboration Strengthens IP Portfolio With Patent Application For Treatment Of Depression
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its... 
Via Benzinga
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.